C‐Met overexpression in node‐positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu

Receptor tyrosine kinases play an important role in malignant transformation of epithelial cells by activating signal transduction pathways important for proliferation, invasion and metastasis. In a pilot study (n = 40), we evaluated expression of the c‐Met and Her2/neu receptor tyrosine kinases and the c‐Met ligand hepatocyte growth factor/scatter factor (HGF/SF) in primary breast cancers and their lymph node metastases using both conventional immunohistochemistry and confocal immunofluorescence. Neither c‐Met and HGF/SF nor Her2/neu expression correlated with established prognostic factors such as age, lymph node involvement, estrogen receptor (ER), progesterone receptor (PR), tumor size, or grade. Both staining methods confirmed a significant correlation between c‐Met overexpression and a high risk of disease progression. Furthermore, among tumors with c‐Met overexpression, only 50% also overexpress Her2/neu, thus identifying a subset of patients with aggressive disease in addition to Her2/neu. Median disease‐free survival in patients with c‐Met overexpressing tumors was 8 months compared to 53 months when c‐Met expression was low (p = 0.037; RR = 3.0). This significant impact of c‐Met on tumor aggressiveness independent of Her2/neu was also confirmed by multivariate analysis. In conclusion, the role of c‐Met expression as a prognostic variable and consequently as an interesting target for novel therapeutic approaches deserves further analysis in a larger cohort of patients.

[1]  D. Hayes,et al.  When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[3]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[4]  D. Rimm,et al.  Tissue microarray‐based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors , 2003, Cancer.

[5]  I. Tsarfaty,et al.  Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells , 2000, Oncogene.

[6]  T. Hirao,et al.  The prognostic significance of amplification and overexpression of c‐met and c‐erb B‐2 in human gastric carcinomas , 1999, Cancer.

[7]  H. Höfler,et al.  Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up , 1999, British Journal of Cancer.

[8]  M. Ogawa,et al.  Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. , 1994, Cancer research.

[9]  B. Teh,et al.  Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. , 2002, Cancer research.

[10]  E. Rimm,et al.  Expression of c‐met is a strong independent prognostic factor in breast carcinoma , 1998, Cancer.

[11]  G. V. Vande Woude,et al.  Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  I. Bièche,et al.  Alteration of Met protooncogene product expression and prognosis in breast carcinomas. , 1999, Analytical and quantitative cytology and histology.

[13]  M. Fiscella,et al.  Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor , 1998, Oncogene.

[14]  K. Miyazaki,et al.  Expression of the hepatocyte growth factor/c‐Met pathway is increased at the cancer front in breast carcinoma , 2001, Pathology international.

[15]  Baljit Singh,et al.  Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. , 2003, Cancer research.

[16]  W. Birchmeier,et al.  Reconstitution of Mammary Gland Development In Vitro: Requirement of c-met and c-erbB2 Signaling for Branching and Alveolar Morphogenesis , 1998, The Journal of cell biology.

[17]  D. Huntsman,et al.  Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy. , 1999, The American journal of pathology.

[18]  E. Lengyel,et al.  Activation Mechanisms of the Urokinase-type Plasminogen Activator Promoter by Hepatocyte Growth Factor/Scatter Factor* , 1999, The Journal of Biological Chemistry.

[19]  N. Harbeck,et al.  HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer. , 1999, International journal of oncology.

[20]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.